Condition: Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer · Sponsor: AGO Study Group
This is an international, multicenter, randomized, open, Phase III trial to evaluate the efficacy and safety of carboplatin/paclitaxel/bevacizumab followed by bevacizumab and niraparib compared to carboplatin/paclitaxel followed by niraparib in patients with newly diagnosed advanced ovarian cancer.
This description comes directly from the study's public registry record.
Sandra Polleis · +49 611 880467 · spolleis@ago-ovar.de
Always discuss trial participation with your own doctor first.
| Klinikum St. Marien Amberg | Amberg, Germany | Recruiting |
| Klinikum Augsburg | Augsburg, Germany | Recruiting |
| Hochtaunus-Kliniken | Bad Homburg, Germany | Recruiting |
| Helios Klinikum Berlin-Buch | Berlin, Germany | Recruiting |
| Onkologische Schwerpunktpraxis Bielefeld | Bielefeld, Germany | Recruiting |
| Städt. Klinikum Brandenburg | Brandenburg an der Havel, Germany | Recruiting |
| Klinikum Bremen Mitte | Bremen, Germany | Recruiting |
| Klinikum Chemnitz | Chemnitz, Germany | Recruiting |
| St. Elisabeth-Krankenhaus Köln-Hohenlind | Cologne, Germany | Recruiting |
| Klinikum Dortmund | Dortmund, Germany | Recruiting |
| Universitätsklinikum Carl Gustav Carus Dresden | Dresden, Germany | Recruiting |
| Florence-Nightingale-Krankenhaus Düsseldorf | Düsseldorf, Germany | Not Yet Recruiting |
+ 53 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05009082